Non steroidal anti-inflammatory drugs (NSAID) 
INTRODUCTION
The development of colon cancer is a multistep process involving inactivation and ectopic activation of different genes, and a morphologic progression from superficial adenomatous polyps to frank, invasive adenocarcinoma [1] . Aberrant crypt foci are generally accepted as precancerous lesions in regard to histopathological characteristics, biochemical and immunohistochemical alterations, as well as genetic and epigenetic alterations [2] . Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models [3] . It is known to act directly by suppressing the cyclooxygenase enzymes (COX-1 and COX-2), which are the rate-limiting enzyme catalyzing the biosynthesis of prostaglandins [4] . Several lines of evidence have demonstrated that COX-2 and its product, PGE 2 , play an important role in the promotion of intestinal tumorigenesis [5] . The pro-tumorigenic effect of COX-2 has been attributed to its ability to enhance cell proliferation and angiogenesis, while inhibiting cell differentiation and apoptosis
[5] , thus, COX-2 is an attractive target in cancer therapy, and understanding the mechanisms involved in controlling its expression are of great interest [6] . Survivin gene is a recently characterized gene located on chromosome 17q25, and a member of the inhibitor of apoptosis protein (IAP) family, whose members inhibit apoptosis through a pathway different from that involving the bcl-2 family [7] . The IAP family of proteins is characterized by the presence of one to three domains, rendering antiapoptotic activity by binding to caspases [8] . The effector caspases-3 and 7 and the initiator caspases-9 are among the caspases that are directly inhibited by human IAP family members (IAP-1, IAP-2, XIAP, and survivin)
[4].
Survivin is mainly localized in the cytoplasm of neoplastic cells, although some tumors may exhibit nuclear expression [9] . Survivin expression has been extensively evaluated in cancer [10] and its expression in normal tissue is developmentally regulated and has been reported to be low in most terminally differentiated tissues. The aberrant high expression of survivin in cancer cells, with little expression in most normal tissues, makes survivin an attractive anticancer target [11] . Also, it was demonstrated that downregulation of expression of antiapoptotic genes such as survivin is responsible for the augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptotic death
[4] . In the current study we aimed to examine the expression of both survivin and COX-2 in early stages of colorectal carcinoma and the effect of acetylsalicylic acid (ASA) on their expression, also if there is any correlation between these two proteins in colon tumorigenesis.
MATERIAL & METHODS

1-Animal study:
Thirty male albino rats at 2 months of age weighing 200-250 g. were used for the study. Rats were divided into 3 groups each of 10 rats. Rats were housed in animal cages with food and water ad libitum with standard laboratory conditions.
2-Animal treatment and experimental design:
Group A received a weekly dose of 0.5 ml of saline subcutaneously for 8 weeks as a negative control.
Group B received a weekly subcutaneous injection of DMH (purchased from Aldrich) at a dose of 12 mg/kg body weight in 0.9 % sodium chloride, pH 6.5 for 8 weeks according to an established protocol for inducing rat colon cancer [12] . Group C received a weekly subcutaneous injection of DMH at a dose of 12 mg/kg body weight in 0.9 % sodium chloride, pH 6.5 for 8 weeks and at the same time the rats were switched to the diet supplemented with 500 p.p.m. aspirin based on the previous report
[13] . 
3-Aberrant Crypt
4-Immunohistochemistry Study:
For immunohistochemistry 5-µM thickness were cut from the paraffin blocks.
The section were deparaffinized with xylene and rehydrated with ethanol. Non enzymatic antigen retrieval was performed in each slide and washed with PBS. Then incubated with primary antibodies for survivin and COX-2 (Lab Vision Co.). Positive signals were detected using Lab Vision Universal Detection Kit according to manufacture protocol.
5-Immunoblotting:
Another part of colon from different groups was homogenized in RIPA buffer containing protease inhibitor cocktail. Samples were centrifuged at 10000 g for 15 minutes and the total protein content of the supernatant was determined.
Thirty µg of total protein were applied then evacuated with gentle application of vacuum using the Slot Blot Filtration Manifold (Hoefer Scientific Instruments, USA). The membrane was incubated in blocking solution PBS pH 7.2 containing 5 % non-fat milk. The membrane then probed with the primary antibodies; anti-COX-2 (1:100) (Lab Vision Co.) and anti-survivin (1:200) (Santa Cruz Biotechnology).
Then the membrane was incubated with secondary antibody (horseradish peroxidase-conjugated goat antimouse) and the color was developed using DAB (3, 3 aminobenzidine tetrahydrochloride). The band density is measured by Scion Image Computer Program.
6-Statistical analysis
The data was statistically analyzed using computer database (SPSS program, Version 13). Data comparisons were performed by using two tailed unpaired student t-test and the correlation between the biochemical parameters were performed using Pearson's correlation coefficient. P value below 0.05 was considered significant.
RESULTS
The ACF assay:
The selected part of the colon was embedded, sectioned and stained. The slides were examined for the presence of ACF (Fig.1 ) that indicates a premalignant lesion induced by the carcinogen (DMH).
Ten specimen for each group were examined in total 30 specimens been examined. Rats that were treated with saline showed no evidence of ACF formation while in DMH-treated rats it was around 82.6 + 3.1 and after aspirin administration it was reduced to 34.9 + 4.5 (p value= 0.0001). In DMH treated group about 53.2 % of AFC were showing the criteria of dysplastic lesion in the form of elevated surface of their mucosa, hematoxylin and eosin stains display the marked nuclear atypia, loss of cell polarity, and increase in mitoses consistent with high-grade dysplasia. After aspirin treatment the percentage has been greatly reduced to 21.7 % showing a 59 % reduction in dysplastic lesions of total AFC. 
Survivin and COX-2 expression
We evaluated the modifications in the expression of survivin and COX-2 in the early stage of colorectal carcinoma and the effect of aspirin on those markers. By IHC we found that survivin was not expressed in normal colorectal mucosa (Fig 2A) while the expression of survivin was observed in the cytoplasm of ACF with relative increase in the dysplastic type and even in the apparently normal mucosa after DMH administration (Fig. 2B) suggesting that the expression of survivin is an essential event in the early stage of colorectal carcinogenesis. Also, we found that aspirin was able to decrease survivin expression indicating the possible role for survivin in the development of aspirin-induced apoptosis (Fig. 2C) . Also, these results were confirmed by imuunoblotting. The results indicate a highly significant increase (P value < 0.001) in the survivin expression in rats' colon injected with DMH and it was found that acetylsalicylic acid (ASA) treatment significantly reduced the levels of survivin (P value < 0.001) (Fig 3) . These results suggest that the anticancerous effect of ASA on the early stages of colorectal carcinoma might be due, at least in part, to the observed reduction in survivin protein levels. C OX-2 expression was also examined by immunohistochemistry (IHC). There was low expression of COX-2 in the cytoplasm of normal colon (Fig. 4A) while it was highly expressed in ACF (Fig. 4B) indicating that COX-2 over-expression is an early event during colon tumorigenesis. After treatment with aspirin it was observed that there is downregulation in the expression of COX-2 ( Fig. 4C) suggesting that COX-2 plays an important role in the development of colorectal cancer and anti-cancerous effect of aspirin is attributable to their ability to inhibit COX-2 overexpression. (Fig.4) . Photomicrograph of mucosa of the colon Showing immunohistochemical expression of COX-2 (A) low expression of COX-2 expression from the normal intestinal mucosa (arrow) (B) mucosa of the colon after DMH administration showing marked upregulation of COX-2 expression in AFC (arrow) (C) intestinal mucosa after treatment with DMH and aspirin at the same time. Notice downregulation of COX2 expression in ACF (arrow). X400 Consistent with IHC, slot blot indicated a marked increase in COX-2 expression in ACF compared with control group (P value < 0.001) and administration of aspirin with the carcinogen has significant reduction in the expression of COX-2 compared to DMH group (P value < 0.001) (Fig.5) . 
3-Correlation:
We found that there is a significant positive correlation between survivin and COX-2 expression both in group treated with DMH and aspirin-treated group (r = 0.816 and r = 0.742 respectively), (Fig. 6 & 7) suggesting that these proteins may have common pathway or affect each other during early stages of colorectal carcinoma. . The subgroup of people with adenoma offers an excellent opportunity for specific chemoprevention with various agents, such as non-steroidal anti-inflammatory drugs (NSAID).
In the present study DMH administration for 8 weeks successfully induced aberrant crypt foci (ACF) which are putative preneoplastic lesion that are believed to be precursors of colorectal carcinoma in rats and possibly in humans [19] . We found that aspirin administration with DMH significantly displayed a 59 % reduction in dysplastic ACF which are truly neoplastic microscopic lesions and have been recognized as the most important lesions in the ACFadenoma-carcinoma sequence. That finding confirms the data of Shpitz et al.
[20] who showed that aspirin-treated patients displayed a reduced proportion of dysplastic ACF from 13.3 % in the positive control group to 6.3 % in aspirin treated group.
For better understanding of the mechanism through which aspirin can exert its chemopreventive effects in the colorectal carcinoma we studied the effect of aspirin on the expression of COX-2 and survivin.
Lian et al. [21] reported that survivin expression is an essential event in the early stages of human colorectal carcinogenesis; this is in accordance with our results which showed complete absence of survivin from normal mucosa and its appearance even in the apparently normal mucosa after DMH administration. In cancer cells, elevated survivin is commonly associated with enhanced proliferative index, reduced levels of apoptosis, resistance to chemotherapy and increased rate of tumor recurrence making antisurvivin therapy an attractive cancer treatment strategy.
In previous study it was observed that ASA does not affect survivin mRNA levels in breast cancer cells suggesting that ASA acts by a posttranscriptional proteasomedependent mechanism to reduce survivin protein levels [22] . Our study worked on protein level as through IHC and immunoblot we found that ASA treatment significantly reduced the levels of survivin indicating that aspirin may exert its chemoprotective effect partially through antagonizing the antiapoptotic effect of survivin protein.
Several preclinical studies have shown that disrupting survivin expression or function in cancer cells decreases their proliferation and enhances apoptosis [11] . Also, Yoo and Lee [4] observed that ASA treatment resulted in a significant decrease in the level of survivin among IAP family in prostate cancer cells.
Recent data suggest that COX-2 is involved in the process of malignant transformation and tumor progression. COX-2 seems to be involved in the development of colorectal cancer according to genetic and pharmacological evidence [23] . It was reported that COX-2 over-expression is important during colorectal carcinoma; however it is unclear exactly where in the multistep process COX-2 deregulation occurs [18] . In the current study, it was found that there is a marked increase in COX-2 expression in ACF compared with control group demonstrating that COX-2 over-expression is an early event during colon tumorigenesis.
In a recent study, it was observed that use of aspirin after a diagnosis of non-metastatic colorectal cancer was associated with a decreased risk of colorectal cancer-specific mortality. This inverse association appeared to be strongest among participants whose primary tumors over-expressed COX-2 [3] . Our results are consistent with these findings as we found that ASA significantly reduce the expression of COX-2 which is of great benefit as over-expression of COX-2 in tumor tissue has been associated with a poorer prognosis among colorectal cancer patients in some studies [24, 25] . Correlation between COX-2 and survivin had been described in the study of Erkanli et al.
[26] who reported that COX-2 and survivin might share a common molecular pathway or enhance each others actions in the developmental pathway of endometrial carcinoma. Younis et al.
[27] showed the same observation in male breast carcinoma as they described the correlation between COX-2, survivin and intratumoral aromatse, and they mentioned that such correlation may have therapeutic implication in the treatment of male and female cancer breast.
To our knowledge it is the first time to describe the correlation between COX-2 and survivin in induced colorectal carcinoma. This correlation appears in DMH-induced aberrant crypt foci and after aspirin treatment. Such correlation between these two proteins should be further investigated to assess potential chemopreventive opportunities for combining COX-2 and survivin inhibitors.
Taken together, we have shown that survivin and COX-2 are overexpressed and positively correlated in early stage of colorectal carcinoma and aspirin can exert a significant effect as a chemoprophylactic agent through downregualtion of these two proteins. So, we think that targeted therapies against survivin and COX-2 may be valuable in chemoprevention and treatment of colorectal carcinoma. colorectal cancer. JAMA; 302 (6): 649-658).
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